γδT Cell Cancer Immunotherapy

Dr. Barisa is currently a Senior Fellow at University College London (UCL), specialising in experimental paediatric oncology, with a particular emphasis on allogeneic, gene-engineered ?dT cell immunotherapy for a range of solid tumour indications. In this capacity she works with two separate groups at UCL’s Zayed Centre of Great Ormond St Hospital, London UK: the Experimental Paediatric Oncology Research Group and the Allogeneic Immunotherapy Research Group. Awarded this year, she is co-investigator on a UCL Technology Fund-supported £2.5million grant to advance late-stage pre-clinical development of a gene-engineered ?dT cell immunotherapy pipeline, among others. She has previously worked on a range of academic and commercial ?dT cell therapy product development pipelines that have resulted in numerous patent applications, covering ?dT cell expansion for clinical use, their transduction with novel lentiviral strategies and new types of efficacy constructs to boost killing of tumour targets.

1. Overview of current knowledge on human ?d T cell biology 2. ?d T cells and tumors: a two-way interaction 3. ?d T cell ‘exhaustion’ as an area for therapeutic intervention 4. What is the evidence for ?d T cell suppression by tumors? 5. Synthetic engineering that is optimized for ?d T cells 6. Updated systematic review of ?d T cell clinical trial data 7. Allograft persistence: the next frontier for allogeneic ?d T cell therapy 8. Allogeneic aßT cells, NK cells and ?d T cells: one allogeneic immunotherapy to rule them all? 9. Where next for ?d T cell immunotherapy? A future Perspective